BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • BCI
    • Ebola outbreak
    • Hantavirus
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Tuesday, June 30, 2026
Home » Blogs » BioWorld MedTech Perspectives » Ultrasound patch could aid in patient healing

BioWorld MedTech Perspectives
BioWorld MedTech Perspectives RSS FeedRSS

Medical technology

Ultrasound patch could aid in patient healing

Aug. 9, 2013
By Omar Ford

WolverineMarvel Comics' popular character Wolverine is known for his ability to heal from nearly any wound. Researchers at Drexel University in Philadelphia have developed an ultrasound technology aimed at giving patients who suffer from chronic wounds, an extra boost in recovering from the injuries.

And while it's not anywhere near the level of Wolverine's powers (he is a fictional character after all), initial studies show promising results for the device. In the study, researchers treated patients suffering from venous ulcers, which account for 80% of all chronic wounds found on lower extremities and affect approximately 500,000 U.S. patients annually, a number that’s expected to increase as obesity rates climb. It’s estimated that treatment for venous ulcers costs the U.S. healthcare system over $1 billion dollars per year.

Researchers applied the device to patients for 15 to 45 minutes, once a week, while they were seeing their physician for a routine appointment. The end results was improved healing compared to the control group that did not receive treatment.

I interviewed some of the researchers involved in this project, and while there are definite plans to try and get this technology into the market place, there is also a sense of urgency.

Joshua Samuels, one of the researchers in the study spoke passionately about the technology and perhaps gave one of the most heartfelt interviews that I have had in my six years here at Medical Device Daily. I think his quote pretty much sums up the pure unbridled mission of med-tech.

“It’s always slow moving getting it from the research lab to the market place,” Samuels said. “What I would really like to see is the device get used by patients as quick as possible. It’s always tough when you do biomedical research knowing that it could take six to seven years to get onto the market place. I know that there are regulations and I know that everything has to go through its due process, but that’s something I would really like to see – to get to patients so that it can help them.”

Here's hoping that happens.

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for June 29, 2026.
  • Illustration for mutations in the DNA leading to brain diseases or neurodegenerative disorders

    ENCALS 2026: From genetics to advancing strategies against ALS

    BioWorld Science
    Amyotrophic lateral sclerosis (ALS)-associated genes provide direct therapeutic targets and reveal pathways that can be used to develop treatments that counteract...
  • Subsense BCI platform

    Next wave of BCI firms builds on pioneers to tackle challenges

    BioWorld
    With the pace of neurotechnology development accelerating, a wave of brain-computer interface (BCI) companies is emerging on the heels of the pioneers. In the...
  • Boehringer Ingelheim identifies new mGlu3 receptor agonists

    BioWorld Science
    Boehringer Ingelheim Pharma GmbH & Co. KG and Vanderbilt University have discovered new dihydrobenzoxazine compounds acting as metabotropic glutamate mGlu3...
  • GT-02897 exerts efficacy in preclinical multiple myeloma

    BioWorld Science
    Investigators from the Karl Landsteiner University aimed to evaluate the therapeutic potential of a novel CDK9 inhibitor/degrader, GT-02897, for the potential...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing